Assessment of Radiological Changes in Primary Central Nervous System Lymphoma Following Corticosteroid Treatment and Its Prognostic Implications for Overall Survival: A Multicenter Analysis

By
Florian Scheichel
D. Pinggera
T. Rossmann
B. Popadic
S. Aspalter
V. Schön
A. Woehrer
M. M. Dorostkar
C. Dorfer
C. F. Freyschlag
F. Marhold
August 29, 2026

Journal Of Neuro-Oncology

1

Primary central nervous system lymphoma (PCNS-LBCL) accounts for approximately 3% of intracranial tumors.
2

Corticosteroid therapy (CST) can lead to significant tumor regression in PCNS-LBCL, but responses vary widely among patients.
3

The study involved a multicenter prospective analysis of patients scheduled for biopsy, with a focus on radiological changes post-CST.
4

Eighteen patients were included in the prospective study after excluding those without a second MRI or with other diagnoses.
5

Survival analysis aimed to determine if the radiological response to CST could predict overall survival in PCNS-LBCL patients.

Original Source(s)

Journal Of Neuro-Oncology

Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study

by Florian Scheichel, D. Pinggera, T. Rossmann, B. Popadic, S. Aspalter, V. Schön, A. Woehrer, M. M. Dorostkar, C. Dorfer, C. F. Freyschlag, F. Marhold
August 29, 2026

Related Content

Nature Medicine

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Dana-Farber

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

by
August 26, 2026
5 min

Jama Network Open